RT Journal Article
T1 Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors
A1 Romero, Miguel E. jimenez
A1 Gallego, Maria Camacho
A1 Serrato, Jose c. navarro
A1 Sanchez Hurtado, Miguel A.
A1 Santotoribio, Jose D.
K1 Prostate cancer
K1 castration-resistant
K1 abiraterone acetate
K1 prednisone
K1 chemo-naive
K1 survival
K1 prognostic models
K1 Clinical-outcomes
K1 Plus prednisone
K1 Antigen
K1 Men
K1 Model
K1 Enzalutamide
K1 Cou-aa-302
K1 Diagnosis
AB Background/Aim: The aim of the study was to evaluate the combined treatment with abiraterone acetate and prednisone (AA+P) in patients with castration resistant prostate cancer (mCPRC), and to identify the survival prognostic factors. Patients and Methods: Patients diagnosed with mCPRC not previously treated with chemotherapy and administered with AA+P were classified into two groups: those with lower and higher survival rates (at 30 months vs. 60 months). Results: A total of 53 patients were studied at the time of mCRPC diagnosis. Patients with the highest survival rate had suffered prostate cancer for >45 months. At the time of initial prostate cancer diagnosis, they belonged to the risk groups 1-4, had pain intensity measured according to the brief pain inventory (BPI) scale of 0-2, were treated with AA+P>16 months, and had the following tumour marker serum levels: LDH baseline 45 months. At the time of initial prostate cancer diagnosis, they belonged to the risk groups 1-4, had pain intensity measured according to the brief pain inventory (BPI) scale of 0-2, were treated with AA+P>16 months, and had the following tumour marker serum levels: LDH baseline 16 months, and had the following tumour marker serum levels: LDH baseline
PB Int inst anticancer research
SN 0250-7005
YR 2021
FD 2021-08-01
LK https://hdl.handle.net/10668/25155
UL https://hdl.handle.net/10668/25155
LA en
DS RISalud
RD Apr 6, 2025